Priya Krishnamurthy, MD
Endocrinology, Diabetes & Metabolism · St George, UTNPI 1821283631
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Amgen accounts for 67.6% of it on its own, with 31 other manufacturers making up the rest. 2025 is the largest year on record at $13,799, 4.6 times the $3,000 reported in 2019.
Across 258 payments — averaging $85.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$15K
- IBSA Pharma Inc.$2K
- Medtronic$2K
- Radius Health, Inc.$539
- Corcept Therapeutics$371
- Lilly USA, LLC$324
- plus $3K from 26 others
What the payments were for
- Consulting fees$1,0005%
- Speaking & faculty fees$12,80258%
- Travel & lodging$1,8318%
- Food & beverage$6,54730%
- Education$50%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 53 | $14,987 |
| IBSA Pharma Inc. | 9 | $1,610 |
| Medtronic(2 entities) | 23 | $1,504 |
| Radius Health, Inc. | 20 | $539 |
| Corcept Therapeutics | 11 | $371 |
| Lilly USA, LLC | 16 | $324 |
| Mannkind Corporation | 11 | $276 |
| Novo Nordisk | 16 | $249 |
| Tandem Diabetes Care, Inc. | 10 | $207 |
| GRT US Holding, Inc. | 5 | $205 |
| AstraZeneca(2 entities) | 7 | $197 |
| Johnson & Johnson | 12 | $190 |
| Sanofi-aventis U.S. LLC | 10 | $174 |
| Recordati_rare_diseases_inc. | 5 | $162 |
| Ascendis Pharma Endocrinology Inc | 3 | $142 |
| Boehringer Ingelheim | 7 | $138 |
| Kyowa Kirin, Inc. | 2 | $136 |
| Dexcom, Inc. | 7 | $128 |
| Abbott | 6 | $119 |
| Madrigal Pharmaceuticals | 2 | $100 |
| BETA Bionics, Inc. | 4 | $99 |
| Xeris Pharmaceuticals, Inc. | 3 | $55 |
| Insulet Corporation | 2 | $50 |
| AbbVie | 3 | $48 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $39 |
| Shire North American Group Inc | 2 | $32 |
| Antares Pharma, Inc. | 1 | $22 |
| Pfizer | 1 | $19 |
| Lundbeck LLC | 1 | $17 |
| Sequel Med Tech, LLC | 1 | $17 |
| Boston Scientific | 1 | $16 |
| Nevro Corp. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,185 in reported general payments places this provider in the 75th percentile of 38 endocrinology, diabetes & metabolism providers in Utah.
See all endocrinology, diabetes & metabolism providers in Utah →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TymlosAbaloparatide | 156 | $429,817 |
| OzempicSemaglutide | 88 | $108,013 |
| TrulicityDulaglutide | 74 | $83,894 |
| Teriparatide | 14 | $40,333 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $35,134 |
| JardianceEmpagliflozin | 43 | $33,456 |
| MounjaroTirzepatide | 24 | $28,729 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $19,547 |
| LevoxylLevothyroxine Sodium | 653 | $15,066 |
| Liothyronine Sodium | 498 | $14,162 |
| Humalog Kwikpen U-200Insulin Lispro | 23 | $13,426 |
| FarxigaDapagliflozin Propanediol | 11 | $10,603 |
| SynthroidLevothyroxine Sodium | 87 | $7,697 |
| Novolog FlexpenInsulin Aspart | 19 | $4,249 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $3,378 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Radius Health, Inc.Tymlos | $539 | $429,817156 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $324 | $112,62398 claims |
| Novo NordiskOzempic | $249 | $108,01388 claims |
| Boehringer IngelheimJardiance | $138 | $33,45643 claims |
| PfizerLevoxyl | $19 | $15,066653 claims |
| AstraZenecaFarxiga | $197 | $10,60311 claims |
| AbbVieSynthroid | $48 | $7,69787 claims |
| IBSA Pharma Inc.Tirosint | $1,610 | $3,01015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 38 endocrinology, diabetes & metabolism providers in Utah.
Other endocrinology, diabetes & metabolism in St George
- Monica MorenoSt George$5K
- Eliot BrintonSalt Lake City$733K
- Claudia FishPark City$286K
- Alireza Falahati-NiniSalt Lake City$241K
- Steven BrownLayton$105K
- Timothy GrahamSandy$90K
- Jack WahlenOgden$70K
- Mohammed NizamProvo$54K
- Shahzad AhmadSalt Lake City$25K
- Vishnu SundareshSalt Lake City$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.